Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM.
Emicerfont is a corticotropin-releasing factor type 1 (CRF1) receptor antagonist with an IC50 of 66 nM[1].
At concentration of 10 mg/kg, Emicerfont reduces i.c.v. CRF-induced gerbil forepaw treading and marmoset defensive postures. Emicerfont also reduces rat pup ultrasonic vocalization at concentration of 30 mg/kg[1].
[1]. Zorrilla EP, et al. Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend. 2013 Mar 1;128(3):175-86.
















